Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air
NCT ID: NCT01994681
Last Updated: 2013-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optical and Biochemical Biomarkers in Early Pancreatic Cancer
NCT03404661
Identification of Biomarkers for Early Detection of Pancreatic Cancer
NCT00897494
Panc CA Risk Model & Biomarker Testing In High-Risk Cohort
NCT05287347
Bio-Repository of High Risk Cohorts for the Early Detection of Pancreas Cancer
NCT03260842
B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosidase Enzymes in the Plasma of Patients With a Localized Cancer.
NCT07236177
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pancreatic Cancer
No interventions assigned to this group
Healthy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pancreatic cancer positive biopsy
* Before any treatment
* Signed Informed Patient Consent
* Healthy patients
* No history of Pancreatic cancer
* Signed Informed Patient Consent
Exclusion Criteria
* Neoadjovant treatment
* Post surgery for Pancreatic cancer
* A history of any other cancer type, except skin cancer that is not melanoma
Healthy Group
* History of Pancreatic cancer
* Pancreatic cancer background in the family
* A history of any other cancer type, except skin cancer that is not melanoma
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Spectrosense Ltd.
INDUSTRY
Rauscher, Gregory E., M.D. PA
INDIV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Martin Gutierrez, MD
Role: PRINCIPAL_INVESTIGATOR
Hackensack Meridian Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hackensack University Medical Center
Hackensack, New Jersey, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
00004108
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.